Russian pharmaceutical company "R-Pharm” according to the agreement with AstraZeneca to produce in Russia the Oxford vaccine from COVID-19, Chairman of the Board of Directors and founder of the "R-Pharm” Alexey Repik.
"We its intent is issued in the form of signed agreements in the field of manufacturing and supplying vaccine developed by AstraZeneca and Oxford University using the technological capabilities "R-Pharm” for the project", — he told on air of TV channel "Russia 24".
According to Repik, "R-Pharm” will become a hub for the supply of vaccines in many countries: middle East, Southeast Asia, Europe and the CIS in 30-50 countries.
"of Course, Russia is always our top priority", — said the founder of the "R-Pharm”.
In the UK the vaccine COVID-19 develop two research centers: the University of Oxford and Imperial College in London. Oxford to conduct human trials began on April 23, partner research serves pharmaceutical company AstraZeneca.
"R-Pharm” specializiruetsya on the development, production and commercialization of high-tech medicines, laboratory equipment and medical equipment. The group operates on the territory of Russia and in CIS countries, USA, Germany and Japan. Shareholders of the Japanese company Mitsui, a share "R-Pharm” also owns RDIF the Russian-Japanese investment Fund.
Relevant data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.